[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1993

Clinical Pharmacology

Author Affiliations

3635 Greenbrier Blvd, No. 155C Ann Arbor, MI 48105

Arch Dermatol. 1993;129(9):1205. doi:10.1001/archderm.1993.01680300135027

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

I was pleased to read the new section of Clinical Pharmacology, edited by Robert S. Stern, MD. It was a well-written and useful summary of systemic dapsone.

I believe, however, that there are several errors. The last paragraph on page 302, column 1 appears to have an improperly broken-up sentence that completely alters the meaning of the paragraph as follows:

Complete blood cell counts, platelet counts, and reticulocyte counts are required prior to treatment followed by monthly counts for 1 to 3 months, and semiannually thereafter in patients with human immunodeficiency virus infection. Complete blood cell counts are recommended every 2 to 3 days for the first 2 to 3 weeks of therapy; if a significant reduction in leukocytes, platelets,....

This should read as follows:

Complete blood cell counts, platelet counts, and reticulocyte counts are required prior to treatment followed by monthly counts for 1 to 3 months, and semiannually

First Page Preview View Large
First page PDF preview
First page PDF preview
×